NCT06636695View on ClinicalTrials.gov

Clinical Efficacy of Platelet-Rich Plasma and Hyaluronic Acid Versus Hyaluronic Acid for Knee Osteoarthritis with MRI Analysis

PHASE3CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

March 9, 2023

Study Completion Date

March 30, 2023

Conditions
Osteoarthritis, Knee
Interventions
DEVICE

Cellular Matrix

Group 1 (Cellular Matrix): Patients randomized to this group will be treated with two intra-articular injections of Cellular Matrix at D0 and M1.

DEVICE

Orthovisc

Group 2 (HA): Patients randomized to this group will be treated with two intra-articular injections of HA alone provided by ORTHOVISC at D0 and M1

Trial Locations (1)

529889

Changi General Hospital, Singapore

All Listed Sponsors
lead

Changi General Hospital

OTHER

NCT06636695 - Clinical Efficacy of Platelet-Rich Plasma and Hyaluronic Acid Versus Hyaluronic Acid for Knee Osteoarthritis with MRI Analysis | Biotech Hunter | Biotech Hunter